Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2019-05-13 Lamond David Director Conversion · Series A Redeemable Convertible Preferred Stock −699,280 0
2019-05-13 Lamond David Director Conversion · Series A Redeemable Convertible Preferred Stock −301,829 0
2019-05-13 Lamond David Director Conversion · Series B Redeemable Convertible Preferred Stock −924,056 0
2019-05-10 EPIQ Capital Group, LLC IA/Managing Member of 10% owne Purchase +4,350 $26.41 $115K 2,835,560
2019-05-10 EPIQ Capital Group, LLC IA/Managing Member of 10% owne Purchase +4,170 $27.58 $115K 2,839,730
2019-05-10 EPIQ Capital Group, LLC IA/Managing Member of 10% owne Purchase +80 $27.05 $2K 2,839,810
2019-05-10 EPIQ Capital Group, LLC IA/Managing Member 10% owner Purchase +4,350 $26.41 $115K 2,822,546
2019-05-10 EPIQ Capital Group, LLC IA/Managing Member 10% owner Purchase +4,170 $27.58 $115K 2,826,716
2019-05-10 EPIQ Capital Group, LLC IA/Managing Member 10% owner Purchase +80 $27.05 $2K 2,826,796
2019-05-08 McLoughlin Margaret Director Grant or award · Stock Option (Right to buy) +91,911 91,911

Page 18 of 18 · 350 trades